KaloBios Pharmaceuticals Inc. (HGEN)
(Delayed Data from OTC)
$1.15 USD
-0.07 (-6.07%)
Updated May 3, 2019 01:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[HGEN]
Reports for Purchase
Showing records 1 - 20 ( 144 total )
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Lenzilumab Identifies a Path Forward in CMML and RAS+ Heme Malignancies
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
2Q22 Results; Soft Pipeline Reset Keeps Us on the Sidelines; GvHD and CMML Programs Progress
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
2Q22: Strategic Capital Allocation towards Partner-Funded Trials
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Lenzilumab Looks to Regain Its Footing with Resource and Focus Realignment
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Lenzilumab and COVID-19 Don''t Pan Out; Downgrade to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
ACTIV-5/BET-B Data Expected in July; We Are Behind Lenzilumab and FDA Outcomes
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
How Big Is the Effect of LENZ in Hospitalized COVID Patients. Data Soon
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
1Q22 Results; Lenzilumab Fully Engaged; Phase 2/3 ACTIV-5/BET-B Data in 2Q22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Industry: Medical - Biomedical and Genetics
1Q22: Upcoming COVID-19 Readout and Subsequent EUA is of Prime Importance
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Despite Effective Vaccines, KOL Call Highlights Need for COVID-19 Therapeutics in Evolving Treatment Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J